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Importance: In the era of widespread revascularization and effective anti-anginal agents, the 49 
prevalence and prognostic impact of anginal symptoms and myocardial ischemia among patients with 50 
stable coronary artery disease are unknown.  51 
 52 
Objective: To describe the current clinical patterns of patients with stable coronary artery disease 53 
and the association of anginal symptoms or myocardial ischemia with clinical outcomes. 54 
 55 
Design: The CLARIFY registry enrolled outpatients with stable CAD during 2009/2010 and followed 56 
them up for 2 years (median, 24.1 months, range 1 day to 3 years) 57 
 58 
Setting: Outpatients in 45 countries.  59 
 60 
Participants: 32 396 outpatients with any of: prior myocardial infarction, chest pain and evidence of 61 
myocardial ischemia, evidence of coronary artery disease on angiography, or prior revascularization. 62 
Of these, 20 402 (63.0%) had undergone a non-invasive test for myocardial ischemia within 12 63 
months of enrolment, and were categorized into four groups: neither angina nor ischemia (n = 13 283; 64 
65.1%); evidence of myocardial ischemia without angina (silent ischemia: n = 3060; 15.0%); anginal 65 
symptoms alone (n = 1843; 9.0%); and both angina and ischemia (n = 2216; 10.9%).  66 
 67 
Main Outcome and Measure: The primary outcome was the composite of cardiovascular death and 68 
non-fatal myocardial infarction. 69 
 70 
Results: Overall, 4059 patients (19.9%) had anginal symptoms and 5276 (25.9%) had evidence of 71 
myocardial ischemia on non-invasive testing. Of 470 cardiovascular deaths or myocardial infarctions, 72 
58.3% occurred in patients without angina or ischemia, 12.3% in patients with ischemia alone, 12.1% 73 
in patients with angina alone, and 17.2% in patients with both. The hazard ratios and 95% confidence 74 
intervals for the primary outcome, relative to patients with neither angina nor ischemia, adjusted for 75 
age, sex, geographic region, smoking status, hypertension, diabetes, and dyslipidemia, were 0.89 76 
(0.67-1.19) (P=.44), 1.46 (1.09-1.95) (P=.01), and 1.76 (1.34-2.30) (P<.001) for ischemia alone, 77 
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angina alone, and both, respectively. Similar findings were observed for cardiovascular death and for 78 
fatal or non-fatal myocardial infarction. 79 
 80 
Conclusions and Relevance: In stable coronary artery disease outpatients, anginal symptoms (with 81 
or without ischemia on non-invasive testing), but not silent ischemia, appear associated with an 82 
increased risk of adverse cardiovascular outcomes. The majority of cardiovascular events occurred in 83 
patients with neither angina nor ischemia. 84 
 85 
Trial Registration: ISRCTN43070564. 86 
 87 
Word count: 346 88 
 89 
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Major changes have occurred in the management of patients with coronary artery disease (CAD), with 91 
increasing use of revascularization
1
 and effective evidence-based secondary prevention therapies, 92 
including lifestyle interventions, statins, angiotensin-converting enzyme inhibitors, and antiplatelet 93 
agents, and the availability of newer antianginal treatments. These factors have dramatically changed 94 
the presentation, management, and prognosis of patients with stable CAD.
2
 95 
 There is uncertainty over what factors determine the prognosis of patients with stable CAD 96 
(i.e. patients with evidence of coronary artery disease but without recent acute myocardial infarction) 97 
in the modern era of widespread revascularization and effective medical treatments. Furthermore, as 98 
a consequence of improved treatments, the prevalence and severity of anginal symptoms and 99 
myocardial ischemia may have diminished. The current analysis aims to describe the prevalence of 100 
anginal symptoms and myocardial ischemia in patients with stable CAD, and their association with 101 
clinical outcomes, using data from the large prospective CLARIFY registry in outpatients with stable 102 
CAD. 103 
 104 
105 
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METHODS 106 
Study Design and Patients 107 
The prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease 108 
(CLARIFY) is a prospective longitudinal registry of 33 283 outpatients with stable CAD. The registry is 109 
observational, does not interfere with clinical management, and does not mandate any specific test, 110 
procedure, or treatment. The rationale and design of the registry have been published previously
3-6
 111 
and are available online at www.clarify-registry.com. Patients were enrolled in 45 countries in Africa, 112 
Asia, Australia, Europe, the Middle East, and the Americas, but not in the United States.  113 
 To be eligible for enrollment, patients had to meet at least one of the following criteria: 114 
documented myocardial infarction >3 months before enrollment; angiographic demonstration of 115 
coronary stenosis >50%; chest pain with evidence of myocardial ischemia (stress electrocardiogram); 116 
or coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) >3 months 117 
before enrolment.  118 
 Patients with hospital admission for cardiovascular (CV) reasons (including revascularization) 119 
in the past 3 months, planned revascularization, or conditions hampering participation or 5-year 120 
follow-up (such as limited cooperation, limited legal capacity, serious non-CV disease or conditions 121 
interfering with life expectancy [eg, cancer or drug abuse], or other severe CV disease [eg, advanced 122 
heart failure, severe valve disease, history of valve repair/replacement]) were excluded.  123 
 Participating physicians were cardiologists, office-based primary care physicians, and 124 
physicians based in hospitals with outpatient clinics. These physicians were selected on the basis of 125 
geographic distribution, location (ie, urban, suburban, or rural areas), and specialty, in order to obtain 126 
an epidemiologically representative dataset in each country. Each physician was requested to recruit 127 
10-15 consecutive outpatients. Each country had a predefined national target of 25 patients per 128 
million inhabitants (range 12.5-50, except for China). Patient enrollment was restricted over a brief 129 
period to achieve near-consecutive enrollment. The first patient was enrolled in November 2009 and 130 
recruitment was completed in June 2010. The study is being conducted in accordance with the 131 
Declaration of Helsinki and local ethical approval was obtained prior to recruitment. All patients gave 132 
written informed consent. The study is registered (ISRCTN43070564). 133 
 134 
Data Collection 135 
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Data were captured by standardized electronic case report forms (eCRFs) completed at baseline and 136 
at annual patient visits. For patients who missed visits, telephone contact with the patient, a 137 
designated relative or contact, or his/her physician was attempted. Where applicable, registries could 138 
be used to retrieve vital status.  139 
 To ensure data quality, on-site audits of 100% of the data were performed in 1% of randomly 140 
selected centers per annum; regular telephone contact was maintained with investigators; and eCRFs 141 
underwent centralized verification for completeness, consistency, and accuracy. At baseline, data 142 
were collected on patient characteristics, risk factors, lifestyle, medical history, physical condition, vital 143 
signs, current symptoms, and treatments. Angina or equivalent symptoms were ascertained by each 144 
physician, defined as necessitating occasional or permanent use of antianginal drugs and categorized 145 
according to the Canadian Cardiovascular Society (CCS) classification (class I indicates angina only 146 
during strenuous or prolonged physical activity; class II indicates slight limitation, with angina only 147 
during vigorous physical activity; class III indicates symptoms with everyday activities of daily living; 148 
class IV indicates inability to perform any activity without angina, or angina at rest).
7
 Congestive heart 149 
failure symptoms were defined as signs and symptoms of either right or left ventricular failure, or both, 150 
confirmed by non-invasive or hemodynamic measurements and categorized according to the New 151 
York Heart Association (NYHA) classification (class I indicates patients with cardiac disease but 152 
without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, 153 
palpitation, dyspnea, or anginal pain. Class II indicates patients with cardiac disease resulting in slight 154 
limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, 155 
palpitation, dyspnea, or anginal pain. Class III indicates patients with cardiac disease resulting in 156 
marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes 157 
fatigue, palpitation, dyspnea, or anginal pain. Class IV indicates patients with cardiac disease 158 
resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or 159 
the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is 160 
increased (patients with class IV NYHA were not enrolled).
8
 Available results of invasive and non-161 
invasive tests were collected, but no test was mandated by the study and there was no standardized 162 
measurement of left ventricular ejection fraction. At each visit, clinical outcomes occurring during the 163 
previous 12 months were recorded. The performance of a non-invasive test for myocardial ischemia 164 
during the prior 12 months was collected, regardless of whether this was a stress electrocardiogram 165 
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(ECG), stress echocardiogram, or nuclear imaging, and regardless of the protocol. In addition, 166 
patients with any positive test that did not lead to revascularization were defined as having evidence 167 
of myocardial ischemia on non-invasive testing (regardless of the extent and severity of ischemia and 168 
the level of exercise or stress achieved). Importantly, positive tests for myocardial ischemia that had 169 
led to revascularization before entry into the registry were not considered in this analysis. 170 
For the purpose of this analysis, we pre-defined the main outcome as the composite of CV 171 
death and myocardial infarction (MI). Additional outcomes of interest were the triple composite of CV 172 
death, MI, or stroke, each of the components of these composite outcomes, all-cause mortality, and 173 
major bleeding (defined as bleeding leading to hospitalization or blood transfusion). Events were 174 
accepted as reported by physicians and were not adjudicated. However, all events were source-175 
verified during the audits. 176 
  177 
Statistical Analysis  178 
Baseline characteristics for the whole population and by subgroup (in Table 1 and eTable 1) are 179 
presented using descriptive statistics with mean (standard deviation [SD]) or median (25
th
, 75
th
 180 
quartiles) for continuous variables, depending on the distribution of the data, and counts and percents 181 
for categorical variables. Baseline values were compared between groups using one-way Analysis of 182 
Variance or the Kruskal-Wallis test for continuous variables, depending on the distribution of the data; 183 
and chi-squared tests for categorical variables. Individual and composite clinical outcomes were 184 
analyzed on a time-to-first event basis. The data were analyzed using Cox proportional hazards 185 
models to calculate hazard ratios (HRs), corresponding 95% confidence intervals (CIs) and P values, 186 
firstly for those who had a test for ischemia compared to those who did not, and secondly among 187 
those with a test for ischemia comparing those who had ischemia and no angina, angina and no 188 
ischemia, or both angina and ischemia with those who did not have angina or ischemia. Adjusted 189 
analyses were performed in which clinical outcomes data were adjusted for baseline differences (age, 190 
sex, geographical region, smoking status, hypertension, diabetes, and dyslipidemia). Additional 191 
analyses also involved adjustments for other elements of medical history or for the REduction of 192 
Atherothrombosis for Continued Health (REACH) risk score for recurrent events in atherothrombosis.
9
 193 
As sensitivity analyses, we examined clinical outcomes in the subgroup of patients with diabetes. The 194 
unadjusted model results were also examined in two subpopulations, males and females, and this 195 
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was extended to include a test for interaction between sex and the combined angina and ischemia 196 
variable in the total population from a further Cox proportional hazards model, which also included 197 
these variables as main effects. Statistical analysis was performed at the Robertson Centre for 198 
Biostatistics at the University of Glasgow, UK, using the SAS (version 9.2, Cary, NC, USA) statistical 199 
program.  200 
 201 
RESULTS 202 
Of the 33 283 patients who were available for analysis at baseline, 196 withdrew and 691 currently 203 
have no follow-up data available for another reason, resulting in 32 396 being available for analysis 204 
(FIGURE 1). Median follow-up was 24.1 months (range, 1 day to 3 years; mean, 23.4 months). Among 205 
the 32 396 patients included in this analysis, 20 402 (63.0%) had undergone a test for myocardial 206 
ischemia in the 12 months prior to enrollment. Patients without a test differed markedly from patients 207 
who had undergone a test, for almost all baseline characteristics (eTable 1): they were younger, more 208 
frequently female, had a more recent diagnosis of CAD, more frequent history of MI, and more 209 
frequent anginal and congestive heart failure (CHF) symptoms. They more frequently received aspirin, 210 
thienopyridines, and beta-blockers, and less frequently received lipid-lowering drugs, including statins. 211 
The rate of use of angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers was 212 
similar between groups. 213 
 At 2-year follow-up, the adjusted HR for the primary outcome was lower in patients who had 214 
undergone a non-invasive test for ischemia before enrollment compared to patients who did not (HR, 215 
0.70; 95% CI, 0.60-0.81; P<.001). In addition, CV death, all-cause death, and MI risks were also lower 216 
in patients with a test (eFigure 1).  217 
 Patients who had undergone a test for myocardial ischemia were categorized according to the 218 
presence or absence of myocardial ischemia on non-invasive testing and the presence or absence of 219 
anginal symptoms (CCS class >0) into four groups (FIGURE 1). The largest group was patients with 220 
neither angina nor ischemia (FIGURE 2). Overall, 4059 patients (19.9%) had anginal symptoms (with or 221 
without ischemia) and 5276 (25.9%) had evidence of myocardial ischemia on non-invasive testing 222 
(with or without angina). The baseline characteristics of these four groups are summarized in TABLE 1. 223 
There were important differences between groups. In particular, compared to patients without angina, 224 
patients with angina were slightly younger, more frequently female, had a slightly higher weight, less 225 
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frequent history of either PCI or CABG, but more frequent history of stroke, asthma/chronic 226 
obstructive pulmonary disease (COPD), treated hypertension, or peripheral arterial disease (PAD). 227 
They also more frequently had symptoms of heart failure, higher systolic and diastolic blood pressure, 228 
higher plasma low-density lipoprotein cholesterol and less frequently underwent coronary 229 
angiography than patients without angina. 230 
 Unadjusted clinical outcomes for the four groups are described in TABLE 2; adjusted 231 
outcomes are shown in FIGURE 3. Given the larger size of the group with neither angina nor ischemia, 232 
58.3% of all CV deaths and MIs occurred in this group, whereas 12.3% occurred in patients with 233 
ischemia alone, 12.1% in those with angina alone, and 17.2% in those with both angina and ischemia. 234 
Therefore, 70.4% of events occurred in patients without evidence of ischemia. Using the group with 235 
neither angina nor ischemia as a reference, and after adjustment for age, sex, geographic region, 236 
smoking status, hypertension, diabetes, and dyslipidemia, the primary outcome of CV death or non-237 
fatal MI was not more frequent in patients with ischemia alone (adjusted HR, 0.89; 95% CI, 0.67-1.19; 238 
P=.44; FIGURE 3). Conversely, the risk of the primary outcome was greater in patients with anginal 239 
symptoms and no evidence of ischemia (adjusted HR, 1.46; 95% CI, 1.09-1.95; P=.01) and in those 240 
with both anginal symptoms and evidence of ischemia (adjusted HR, 1.76; 95% CI, 1.34-2.30; 241 
P<.001; FIGURE 3). The four-way variable “presence of angina and/or ischemia” was a highly 242 
statistically significant predictor of the primary outcome (P<.001, after adjustment for age, sex, 243 
geographic region, smoking status, hypertension, diabetes, and dyslipidemia). Similar observations 244 
were made for various secondary outcome measures (including the triple composite outcome of CV 245 
death, myocardial infarction, or stroke), except for stroke and major bleeds, in which there were no 246 
statistically significant difference between groups (FIGURE 3).  247 
 Sensitivity analyses were performed to ensure the robustness of the results. Firstly, there was 248 
no statistically significant interaction with sex or diabetes for each of the outcomes analyzed.  249 
Specifically, the P-values obtained from the tests for interaction in the Cox Proportional Hazards 250 
Models indicate that there is no evidence of any statistically significant differences between males and 251 
females (eTables 2 to 4). Secondly, the effects of angina and ischemia on CV death or MI relative to 252 
the group of patients with neither were assessed after various adjustment methods. Results were 253 
similar, regardless of whether event rates were unadjusted, adjusted for age, sex, geographical region 254 
and smoking status, further adjusted for hypertension, MI, asthma/COPD, stroke, PAD, and diabetes, 255 
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further adjusted for the type of practice (hospital based or not, primary care or not), or adjusted for the 256 
REACH score of recurrent events (eTable 5). Finally, a sensitivity analysis for the primary outcome 257 
was performed in the subset of patients with diabetes mellitus (n = 5942) and its findings were 258 
directionally consistent with the overall results (eFigure 2), although there was no statistically 259 
significant increase in adjusted event rates in the group with angina alone. 260 
 Since anginal symptoms appeared to be a major determinant of the risk of CV death and MI, 261 
we examined the relationship between angina CCS class and outcomes. Relative to patients without 262 
angina (n = 16 343, 80.1%), those with CCS class I angina (n = 1252; 6.1%) had an adjusted HR for 263 
the primary outcome of 1.86 (95% CI, 1.36-2.53; P<.001), whereas it was 1.47 (95% CI 1.11-1.95; 264 
P=.007) for patients with CCS class II (n = 2153; 10.6%) and 1.76 (95% CI, 1.15-2.71; P=.009) for 265 
patients with CCS class III or IV (n = 651; 3.2%). 266 
 267 
268 
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DISCUSSION 269 
The main findings of this analysis are that the vast majority of outpatients with stable CAD have 270 
neither anginal symptoms nor evidence of myocardial ischemia. Among patients who had undergone 271 
a test for myocardial ischemia, approximately 20% suffered from anginal symptoms and 25% had 272 
evidence of myocardial ischemia. After 2 years of follow-up, the presence of anginal symptoms was 273 
associated with worse clinical outcomes regardless of the presence of myocardial ischemia on non-274 
invasive testing, whereas ischemia alone was not. 275 
 There are several important clinical implications of these findings. Firstly, anginal symptoms 276 
alone, even without evidence of myocardial ischemia, were associated with high event rates and 277 
identify a group of patients at high risk of CV death or MI. It is well known that there can be an 278 
important disconnect between anginal symptoms and evidence of myocardial ischemia.
10
 Conversely, 279 
our findings should not be interpreted as detracting from the value of treating ischemia, as our 280 
patients were treated, and there is clear evidence that the presence and severity of myocardial 281 
ischemia are important correlates of prognosis in stable CAD,
11-14
 and possibly of the benefit of 282 
revascularization.
15-18
 A large international trial, ISCHEMIA (NCT01471522), is exploring whether 283 
angiography with a view to revascularization in addition to optimal medical management is superior to 284 
optimal medical management alone in patients with myocardial ischemia. Finally, the majority of CV 285 
deaths and MIs occurred in patients with neither angina nor ischemia, emphasizing the importance of 286 
implementing optimal medical therapy and preventive measures regardless of symptoms or ischemia. 287 
Approximately 70% of events occurred in patients with no evidence of myocardial ischemia on non-288 
invasive testing, therefore focusing management of stable CAD solely on the prevention or treatment 289 
of ischemia does not address the risks incurred by these patients. ,   290 
Some of our findings are expected. Firstly, ischemia was present in approximately 25% of patients of 291 
a stable CAD population who had undergone stress testing, a proportion similar to that seen in a 292 
previous study.
19
 Also, patients with symptomatic ischemia were at higher risk than patients with no 293 
angina or ischemia or patients with silent ischemia. The presence of anginal symptoms was more 294 
frequent in women than in men, was associated with an increased risk of CV outcomes, consistent 295 
with the wealth of evidence documenting the prognostic impact of angina,
20
 including among 296 
outpatients,
21
 both in men and women.
22,23
 It is, however, somewhat unexpected that patients with 297 
anginal symptoms in daily life but no evidence of inducible ischemia were at higher risk than patients 298 
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with asymptomatic ischemia. These findings appear at odds with results from the Heart and Soul 299 
Study,
19
 where myocardial ischemia rather than anginal symptoms appeared key in determining 300 
clinical prognosis, as well as with those from the BARI-2D trial in a diabetic population,
24
 where 301 
angina presence or severity did not appear to affect mortality and cardiovascular outcomes, 302 
prompting the conclusion that "ischemia dictates outcome, not symptoms".
25
 Of note, the prevalence 303 
of anginal symptoms was very high in the BARI-2D population,
24
 with 82% of patients being 304 
characterized as having angina or angina equivalents (compared to approximately 20% in the present 305 
study). There are several potential explanations for why patients with anginal symptoms but no 306 
evidence of myocardial ischemia on non-invasive testing may fare worse than patients with silent 307 
ischemia. Firstly, because anginal symptoms may severely impair exercise capacity, these patients 308 
may not have achieved the same level of exercise as patients with silent ischemia. Thus, anginal 309 
symptoms may prevent completion of a full exercise test and, therefore, the identification of ischemia 310 
by non-invasive testing. Unfortunately, the CLARIFY registry did not collect information regarding the 311 
level of exercise reached during testing. Another explanation is that patients with anginal symptoms 312 
but no evidence of ischemia have substantially more symptoms of heart failure at baseline than 313 
patients with ischemia alone. It is conceivable that what is interpreted by patients and physicians as 314 
anginal symptoms may really be related to heart failure. Note, however, that despite the major 315 
differences in baseline characteristics between the four groups in the current study, adjustment of 316 
outcomes on the REACH risk score did not modify the results. Finally, not all datasets have found that 317 
asymptomatic myocardial ischemia is prognostic,
26
 which is consistent with the fact that acute cardiac 318 
events often stem from rupture or erosion of plaques that are not severe enough to cause 319 
ischemia.
27,28
  320 
 321 
Strengths and Limitations 322 
There are some important limitations to the present analysis. Firstly, the outcome events were not 323 
adjudicated, but were based on investigator reporting. Angina was ascertained by physician 324 
evaluation, as opposed to patient self-reporting of angina using standardized questionnaires
29
 or to 325 
angina observed during a calibrated stress test, but as such may reflect routine clinical practice where 326 
such questionnaires are rarely, if ever, used. The non-invasive tests performed prior to enrolment to 327 
categorize the presence or absence of myocardial ischemia were not standardized in terms of 328 
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background medical therapy, type of test or protocol for the test, and time elapsed between 329 
performance of the test and enrollment. However, conversely, this enhances the clinical applicability 330 
of our results, as they pertain to the presence or absence of myocardial ischemia, regardless of the 331 
test type, date and protocol. Also, the CLARIFY registry did not collect information on the extent or 332 
severity of ischemia, which is an important correlate of prognosis.
30
 There is inception variability in 333 
this cohort, with a mean follow-up of approximately 2 years, while the median time since diagnosis 334 
was 5 years. It is conceivable that most patients with anginal symptoms and evidence of ischemia 335 
might have been offered revascularization before entry into the registry, and, therefore, CLARIFY 336 
patients who have angina despite having been considered for revascularization may be either too sick 337 
to be revascularized (because of diffuse/severe disease and/or because of severe comorbidities) or 338 
may be those in whom revascularization has failed to cure symptoms. Therefore, patients with angina 339 
in this “non-inception cohort” may represent a selected group of high-risk patients, although this was 340 
accounted in part by adjusting for risk factors at entry. Lastly, while the cohort studied is large and has 341 
broad geographic representation, no patients were enrolled in the United States.  342 
There are also important strengths in the present analysis: the cohort is large and 343 
contemporary, the use of evidence-based therapies was high, and the results were robust and 344 
consistent regardless of the various adjustment methods and across several sensitivity analyses. 345 
 346 
CONCLUSION 347 
The majority of stable CAD outpatients have neither angina nor ischemia. The presence of anginal 348 
symptoms in daily life appears associated with a higher risk of CV death or MI than ischemia alone. 349 
Presence of both is associated with the worst outcomes. 350 
 351 
352 
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Figure Legends 495 
 496 
Figure 1. Description of the Population Studied 497 
 498 
Figure 2. Clinical Patterns of Stable CAD Based Upon Presence of Anginal Symptoms and Evidence 499 
of Myocardial Ischemia on Non-Invasive Testing in the CLARIFY Stable CAD Population  500 
CAD, coronary artery disease. 501 
 502 
Figure 3. HRs, 95% CIs and P Values for the Primary Outcome and Various Composite Outcomes, 503 
for Patients With Ischemia and No Angina, Angina and No Ischemia, and Both Angina and Ischemia, 504 
all Relative to Those With Neither Angina nor Ischemia 505 
Outcomes are adjusted for age, sex, geographical region, smoking status, hypertension, dyslipidemia, 506 
and diabetes. *Fatal or non-fatal. CI, confidence interval; CV, cardiovascular; HR, hazard ratio; MI, 507 
myocardial infarction. 508 
 509 
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Table 1. Baseline Characteristics of Patients According to Presence or Absence of Angina and of Ischemia 511 
 Neither Angina nor 
Ischemia (n = 13 283) 
Ischemia and no 
Angina (n = 3060) 
Angina and no 
Ischemia (n = 1843) 
Both Angina and 
Ischemia (n = 2216) 
P 
Value
a
 
Age, mean (SD), y  64.8 (10.3) 64.9 (10.1) 64.4 (10.0) 63.3 (10.3) <.001 
Men, No. (%) 10 747 (80.9) 2427 (79.3) 1326 (71.9) 1576 (71.2) <.001 
BMI, median (Q1, Q3), kg/m
2
  27.4 (25.1, 30.4) 27.6 (25.0, 30.6) 28.4 (25.7, 31.6) 28.1 (25.5, 31.2) <.001 
Weight, median (Q1, Q3), kg 80 (70, 89) 79 (70, 89) 82 (72, 92) 80 (71, 90) <.001 
Ethnicity      
  Caucasian 9088 (68.4) 2123 (69.4) 1519 (82.4) 1702 (76.8)  
  South Asian 695 (5.2) 213 (7.0) 111 (6.0) 165 (7.4)  
  Chinese 153 (1.2) 82 (2.7) 24 (1.3) 65 (2.9)  
  Japanese/Korean 234 (1.8) 49 (1.6) 6 (0.3) 4 (0.2) <.001 
  Hispanic 721 (5.4) 207 (6.8) 36 (2.0) 85 (3.8)  
  Black/African 128 (1.0) 30 (1.0) 33 (1.8) 18 (0.8)  
  Unknown 2264 (17.0) 356 (11.6) 114 (6.2) 177 (8.0)  
Time since first CAD diagnosis, median (Q1, Q3), y  5 (2, 10) 5 (2, 10) 6 (3, 12) 5 (2, 10) <.001 
Medical history, No. (%)      
  Myocardial infarction 7464 (56.2) 1664 (54.4) 1040 (56.4) 1159 (52.3) .003 
  PCI 8375 (63.1) 1728 (56.5) 929 (50.4) 844 (38.1) <.001 
  CABG 3685 (27.7) 818 (26.7) 444 (24.1) 438 (19.8) <.001 
  Hospitalization for CHF 389 (2.9) 182 (5.9) 108 (5.9) 166 (7.5) <.001 
  Stroke 383 (2.9) 108 (3.5) 77 (4.2) 120 (5.4) <.001 
  Asthma/COPD 955 (7.2) 258 (8.4) 192 (10.4) 236 (10.6) <.001 
  Family history of premature CAD 3870 (29.1) 950 (31.0) 694 (37.7) 860 (38.8) <.001 
  Treated hypertension 9072 (68.3) 2279 (74.5) 1435 (77.9) 1784 (80.5) <.001 
  Diabetes 3664 (27.6) 1012 (33.1) 541 (29.4) 725 (32.7) <.001 
  Dyslipidemia 10 361 (78.0) 2486 (81.3) 1519 (82.4) 1821 (82.2) <.001 
  Peripheral artery disease 1271 (9.6) 350 (11.4) 233 (12.6) 353 (15.9) <.001 
Smoking status, No. (%)      
  Current 1360 (10.2) 338 (11.0) 244 (13.3) 303 (13.7)  
  Former 6611 (49.8) 1379 (45.1) 862 (46.8) 879 (39.7) <.001 
  Never 5312 (40.0) 1343 (43.9) 734 (39.9) 1034 (46.7)  
CHF symptoms including NYHA class, No. (%)      
No CHF 12 469 (93.9) 2755 (90.0) 1361 (73.9) 1457 (65.7)  
CHF NYHA Class II 722 (5.4) 251 (8.2) 400 (21.7) 613 (27.7) <.001 
CHF NYHA Class III 90 (0.7) 54 (1.8) 82 (4.4) 146 (6.6)  
512 
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Table 1. Baseline Characteristics of Patients According to Presence or Absence of Angina and of Ischemia (continued) 513 
 Neither Angina nor 
Ischemia (n = 13 283) 
Ischemia and no 
Angina (n = 3060) 
Angina and no 
Ischemia (n = 1843) 
Both Angina and 
Ischemia (n = 2216) 
P 
Value
a
 
HbA1C, mean (SD), % 6.8 (2.1) 6.8 (1.3) 7.2 (3.9) 6.9 (1.4) .002 
Creatinine concentration, median (Q1, Q3), mmol/L 0.088 (0.076, 0.101) 0.088 (0.075, 0.101) 0.088 (0.078, 0.103) 0.089 (0.078, 0.105) <.001 
Total cholesterol, median (Q1, Q3), mmol/L 4.2 (3.6, 4.8) 4.3 (3.6, 4.9) 4.5 (3.8, 5.3) 4.8 (4.0, 5.6) <.001 
HDL, median (Q1, Q3), mmol/L 1.2 (1.0, 1.4) 1.2 (1.0, 1.4) 1.2 (1.0, 1.4) 1.2 (1.0, 1.4) .16 
LDL, median (Q1, Q3), mmol/L 2.3 (1.9, 2.8) 2.3 (1.9, 2.9) 2.5 (2.0, 3.2) 2.6 (2.0, 3.3) <.001 
Fasting triglycerides, median (Q1, Q3), mmol/L 1.3 (1.0, 1.8) 1.4 (1.0, 1.9) 1.5 (1.1, 2.0) 1.5 (1.1, 2.1) <.001 
Heart rate (palpation), mean (SD), bpm 66.6 (10.2) 68.2 (10.5) 68.1 (10.7) 70.2 (11.2) <.001 
Heart rate (ECG), mean (SD), bpm 65.5 (10.9) 67.3 (11.3) 67.2 (11.4) 69.7 (12.0) <.001 
Systolic BP, mean (SD), mmHg 130.5 (16.0) 130.4 (16.2) 132.8 (17.3) 134.3 (17.2) <.001 
Diastolic BP, mean (SD), mmHg 76.6 (9.4) 76.6 (9.6) 77.8 (10.6) 79.7 (10.8) <.001 
LVEF
b
, mean (SD), %  57.4 (10.8) 55.8 (11.4) 56.1 (10.3) 55.8 (10.4) <.001 
Coronary angiography, No. (%)      
   Not done 1038 (7.8) 386 (12.6) 350 (19.0) 744 (33.6) <.001 
   No or minimal vessel disease 411 (3.4) 98 (3.7) 102 (6.8) 96 (6.5)  
   Single vessel disease 5027 (41.1) 872 (32.7) 545 (36.5) 452 (30.7) <.001 
   Multivessel disease 6795 (55.5) 1698 (63.6) 846 (56.7) 922 (62.7)  
Treatments at baseline, No. (%)      
  Aspirin 11 464 (86.3) 2668 (87.2) 1612 (87.5) 1964 (88.6) .02 
  Thienopyridine 3486 (26.3) 765 (25.0) 400 (21.7) 513 (23.2) <.001 
  Beta-blocker 9865 (74.3) 2271 (74.2) 1411 (76.6) 1693 (76.4) .04 
  ACEi and/or ARB 9891 (74.5) 2366 (77.3) 1439 (78.1) 1789 (80.7) <.001 
  Lipid-lowering drug 12 451 (93.7) 2826 (92.4) 1714 (93.0) 2028 (91.5) <.001 
  Statin 11 199 (84.3) 2487 (81.3) 1570 (85.2) 1812 (81.8) <.001 
REACH risk score, mean (SD) 10.8 (3.1) 11.2 (3.2) 11.3 (3.1) 11.5 (3.3) <.001 
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; bpm, beats per minute; CABG, 514 
coronary artery bypass graft; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; Cx, circumflex; 515 
ECG, electrocardiogram; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LAD, left anterior descending; LDL, low-density lipoprotein; LVEF, left 516 
ventricular ejection fraction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; RCA, right coronary artery; SD, standard 517 
deviation; Q1, first quartile; Q3, third quartile.  518 
a
P values pertain to the overall comparison between the four groups. 519 
b
LVEF measurement available in 14 968 patients.  520 
 521 
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Table 2. Unadjusted 2-Year Event Percentages for the Four Patient Groups  522 
 523 
 Neither Angina 
nor Ischemia  
(n = 13 283) 
Ischemia and 
no Angina  
(n = 3060) 
Angina and 
no Ischemia 
(n = 1843) 
Both Angina 
and Ischemia 
(n = 2216) 
P 
Value
a
 
Primary outcome: CV 
death or MI, % 
2.10 1.92 3.12 3.72 <.001 
CV death, MI, 
stroke, % 
2.74 2.51 3.89 4.41 <.001 
CV death, % 1.17 1.02 1.36 2.07 .003 
MI,
b
 %
 
1.34 1.26 2.36 2.34 <.001 
Stroke,
b
 %
 
0.81 0.73 1.04 1.06 .43 
All-cause death, % 2.64 2.81 2.93 3.52 .12 
Major bleed, % 0.86 0.77 0.66 0.65 .66 
Abbreviations: CV, cardiovascular; MI, myocardial infarction; revasc. 524 
a
P values pertain to the overall comparison between the four groups from an unadjusted Cox 525 
Proportional Hazards model. 526 
b
Fatal and non-fatal.  527 
 528 
Neither angina
nor ischemia
(n = 13 283)
Angina and
no ischemia
(n = 1843)
Underwent non-invasive testing for ischemia (n = 20 402)
Available for analysis (n = 32 396)
Did not undergo testing (n = 11 994)
Ischemia and
no angina
(n = 3060)
Both angina
and ischemia
(n = 2216)
Patients enrolled in CLARIFY
(n = 33 283)
 Withdrew participation (n = 196)
 Follow up not available (n = 691)
Angina and
no ischemia
(n = 1843)
9.0%
Ischemia and
no angina
(n = 3060)
15.0%
Both angina
and ischemia
(n = 2216)
10.9%
Neither angina
nor ischemia
(n = 13 283)
65.1%
Higher riskLower risk
P Value
.44
.01
<.001
HR (95% Cl)
0.89 (0.67-1.19)
1.46 (1.09-1.95)
1.76 (1.34-2.30)
.37
.02
<.001
0.89 (0.70-1.15)
1.38 (1.06-1.80)
1.58 (1.24-2.02)
.42
.35
<.001
0.85 (0.58-1.26)
1.23 (0.80-1.90)
1.90 (1.33-2.70)
.66
.004
.004
0.92 (0.65-1.31)
1.67 (1.18-2.36)
1.66 (1.18-2.34)
.45
.45
.49
0.84 (0.53-1.33)
1.22 (0.74-2.01)
1.19 (0.73-1.94)
.85
.45
.02
1.02 (0.81-1.30)
1.12 (0.84-1.50)
1.37 (1.05-1.77)
.46
.35
.40
0.84 (0.54-1.32)
0.75 (0.41-1.38)
0.78 (0.43-1.40)
0 1
HR (95% Cl)
2 3 4
CV death, non-fatal MI
   Ischemia only
   Angina only
   Both
CV death, MI-stroke
   Ischemia only
   Angina only
   Both
CV death
   Ischemia only
   Angina only
   Both
MI*
   Ischemia only
   Angina only
   Both
Stroke*
   Ischemia only
   Angina only
   Both
All-cause death
   Ischemia only
   Angina only
   Both
Major bleed
   Ischemia only
   Angina only
   Both
